相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A review of cancer immunotherapy toxicity
Lucy Boyce Kennedy et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
Shugeng Gao et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study
Chiara Pozzessere et al.
ERJ OPEN RESEARCH (2020)
Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma
Tomohisa Baba et al.
FUTURE ONCOLOGY (2019)
Immune Checkpoint Inhibitors in Lung Cancer and Melanoma
Kathleen Madden et al.
SEMINARS IN ONCOLOGY NURSING (2019)
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Jacques Cadranel et al.
EUROPEAN RESPIRATORY REVIEW (2019)
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
Yuankai Shi et al.
LANCET HAEMATOLOGY (2019)
Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors
David Hsiehchen et al.
JAMA NETWORK OPEN (2019)
Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
Erwin H. J. Tonk et al.
CASE REPORTS IN ONCOLOGY (2019)
Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event
Mizuki Nishino et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
Karthik Suresh et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Severe acute interstitial lung disease after nivolumab in three non-small cell lung cancer patients with imaging findings of airway obstruction adjacent to lung tumors
Kenji Nakahama et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2017)
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Shunsuke Teraoka et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
Sarah Chuzi et al.
CANCER MANAGEMENT AND RESEARCH (2017)
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
Monica Khunger et al.
CHEST (2017)
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2016)
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Don S. Dizon et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis
Mizuki Nishino et al.
JAMA ONCOLOGY (2016)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
分享论文
